HU227397B1 - Pharmaceutical formulations containing darifenacin - Google Patents

Pharmaceutical formulations containing darifenacin Download PDF

Info

Publication number
HU227397B1
HU227397B1 HU0500976A HUP0500976A HU227397B1 HU 227397 B1 HU227397 B1 HU 227397B1 HU 0500976 A HU0500976 A HU 0500976A HU P0500976 A HUP0500976 A HU P0500976A HU 227397 B1 HU227397 B1 HU 227397B1
Authority
HU
Hungary
Prior art keywords
darifenacin
release
tablet
acceptable salt
pharmaceutically acceptable
Prior art date
Application number
HU0500976A
Other languages
English (en)
Hungarian (hu)
Inventor
Thomas Francis Dolan
Michael John Humphrey
Donald John Nichols
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10780813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU227397(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HU0500976D0 publication Critical patent/HU0500976D0/hu
Publication of HU227397B1 publication Critical patent/HU227397B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0500976A 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin HU227397B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9518953.6A GB9518953D0 (en) 1995-09-15 1995-09-15 Pharmaceutical formulations
PCT/EP1996/003719 WO1997009980A1 (en) 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin

Publications (2)

Publication Number Publication Date
HU0500976D0 HU0500976D0 (en) 2005-12-28
HU227397B1 true HU227397B1 (en) 2011-05-30

Family

ID=10780813

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0500976A HU227397B1 (en) 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin
HU9802339A HU225236B1 (en) 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU9802339A HU225236B1 (en) 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin

Country Status (32)

Country Link
US (1) US6106864A (OSRAM)
EP (2) EP1245231B1 (OSRAM)
JP (1) JP3403203B2 (OSRAM)
KR (1) KR100348585B1 (OSRAM)
CN (1) CN1303998C (OSRAM)
AR (1) AR005231A1 (OSRAM)
AT (2) ATE269076T1 (OSRAM)
BR (2) BR9610153A (OSRAM)
CA (1) CA2230314C (OSRAM)
CO (1) CO4750822A1 (OSRAM)
CY (3) CY2468B1 (OSRAM)
CZ (1) CZ294024B6 (OSRAM)
DE (4) DE69632753T2 (OSRAM)
DK (2) DK0850059T3 (OSRAM)
EG (1) EG23826A (OSRAM)
ES (2) ES2224002T3 (OSRAM)
FR (1) FR05C0019I2 (OSRAM)
GB (1) GB9518953D0 (OSRAM)
HU (2) HU227397B1 (OSRAM)
IL (1) IL122746A (OSRAM)
LU (1) LU91163I2 (OSRAM)
MY (1) MY125662A (OSRAM)
NL (1) NL300190I2 (OSRAM)
NO (2) NO314783B1 (OSRAM)
NZ (1) NZ316924A (OSRAM)
PL (1) PL185604B1 (OSRAM)
PT (1) PT1245231E (OSRAM)
RU (1) RU2163803C2 (OSRAM)
TR (1) TR199800461T1 (OSRAM)
TW (1) TW442300B (OSRAM)
WO (1) WO1997009980A1 (OSRAM)
ZA (1) ZA967745B (OSRAM)

Families Citing this family (313)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502302A (ja) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US7858119B1 (en) * 2000-05-09 2010-12-28 Amina Odidi Extended release pharmaceuticals
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
GB0129962D0 (en) 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
DK1664036T3 (da) * 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
EA009941B1 (ru) * 2003-10-03 2008-04-28 Пфайзер Инк. Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0402491D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Medicaments
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
US7687533B2 (en) * 2004-03-18 2010-03-30 Pfizer Inc. N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides
US20050215542A1 (en) * 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
BRPI0507877A (pt) * 2004-03-23 2007-07-24 Pfizer derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
US7538141B2 (en) * 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
JP2007532526A (ja) * 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ［４，３−ｄ］ピリミジン類
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MXPA06014486A (es) * 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
HRP20080608T3 (hr) 2004-08-12 2008-12-31 Pfizer Inc. Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EA011725B1 (ru) * 2004-08-26 2009-04-28 Пфайзер Инк. Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
EA013678B1 (ru) 2004-08-26 2010-06-30 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
BRPI0517925A (pt) * 2004-11-02 2008-10-21 Pfizer derivados de sulfonil benzimidazol
US20060111416A1 (en) * 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
BRPI0608436A2 (pt) 2005-03-17 2009-12-29 Pfizer derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor
EP1866278A1 (en) * 2005-03-28 2007-12-19 Pfizer, Inc. Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US7645786B2 (en) * 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US20070149464A1 (en) * 2005-06-15 2007-06-28 Pfizer Inc. Combination
CN101228134A (zh) * 2005-06-15 2008-07-23 辉瑞有限公司 用作杀寄生虫剂的取代芳基吡唑
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ZA200802811B (en) 2005-09-02 2009-09-30 Theravida Inc Therapy for the treatment of disease
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2660261A1 (en) * 2006-08-09 2008-02-14 Pfizer Products Inc. Heterocycles useful as inhibitors of carbonic anhydrase
US8278355B2 (en) * 2006-09-12 2012-10-02 Therexcell Pharma Inc. Isovaline for treatment of pain
KR101109866B1 (ko) * 2006-09-21 2012-04-12 라퀄리아 파마 인코포레이티드 선택성 산 펌프 억제제로서의 벤즈이미다졸 유도체
ATE520651T1 (de) 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
RU2322998C1 (ru) * 2006-11-16 2008-04-27 Общество с ограниченной ответственностью "Березовый мир" Носитель лекарственных и диагностических средств
KR101107949B1 (ko) * 2007-02-02 2012-02-08 화이자 프로덕츠 인코포레이티드 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009105887A1 (en) * 2008-02-26 2009-09-03 Ernest Puil Cyclic amino acids for the treatment of pain
WO2009140078A1 (en) * 2008-05-16 2009-11-19 The Procter & Gamble Company Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
US20110217387A1 (en) * 2008-05-16 2011-09-08 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
ES2465478T3 (es) * 2008-05-30 2014-06-05 Ucb Pharma, S.A. Composiciones farmacéuticas que comprenden brivaracetam
CA2731368C (en) * 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
JP5621148B2 (ja) 2008-11-21 2014-11-05 ラクオリア創薬株式会社 ５−ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール−３−カルボキサミド誘導体
NZ593473A (en) 2009-01-12 2013-02-22 Pfizer Ltd Sulfonamide derivatives
WO2010103070A2 (en) 2009-03-12 2010-09-16 Charité - Universitätsmedizin Berlin Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2236516A1 (en) 2009-03-31 2010-10-06 Charité-Universitätsmedizin Berlin (Charité) Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury
JP2012528140A (ja) 2009-05-29 2012-11-12 ファイザー・リミテッド 新規なグルココルチコイド受容体アゴニスト
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
US8617763B2 (en) * 2009-08-12 2013-12-31 Bloom Energy Corporation Internal reforming anode for solid oxide fuel cells
US20130045948A1 (en) 2009-12-11 2013-02-21 E I Du Pont De Nemours And Company Azocyclic inhibitors of fatty acid amide hydrolase
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
WO2011161504A1 (en) * 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
CA2803118C (en) 2010-07-09 2015-11-03 Pfizer Limited Sulfonamide derivatives as nav 1.7 inhibitors
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN105330675A (zh) 2010-11-15 2016-02-17 Viiv保健英国有限公司 Hiv复制的抑制剂
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
JP5931933B2 (ja) 2011-02-25 2016-06-08 武田薬品工業株式会社 Ｎ−置換オキサジノプテリジンおよびオキサジノプテリジノン
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
AP2013007159A0 (en) 2011-04-05 2013-10-31 Pfizer Ltd Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP3167885A1 (en) 2011-05-10 2017-05-17 TheraVida, Inc. Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
WO2012154775A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
EP2710002B1 (en) 2011-05-18 2017-03-01 RaQualia Pharma Inc Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
MX2014001354A (es) 2011-08-02 2014-10-14 Pfizer Crizotinib para uso en el tratamiento de cancer.
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
MX2014004743A (es) 2011-10-19 2014-08-01 Zoetis Llc Uso de derivados de aminoacetonitrilo contra endoparasitos.
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
CN103906746B (zh) 2011-10-26 2015-12-09 辉瑞有限公司 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
CA2853231C (en) 2011-10-28 2020-08-04 Inhibitaxin Limited Pyridazine derivatives with autotaxin activity for use in therapy
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CN102600096B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种达非那新缓释制剂及其制备方法
CN102579379B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种药物缓释制剂及其制备方法
WO2013102826A1 (en) 2012-01-04 2013-07-11 Pfizer Limited N-aminosulfonyl benzamides
EP2809655B1 (en) 2012-02-03 2015-08-12 Pfizer Inc Benziimidazole and imidazopyridine derivatives as sodium channel modulators
PT2822953T (pt) 2012-03-06 2017-04-06 Pfizer Derivados macrocíclicos para o tratamento de doenças proliferativas
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
WO2013152135A1 (en) 2012-04-04 2013-10-10 Dawei Zhang Substituted quinolines as bruton's tyrosine kinases inhibitors
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
JP6463680B2 (ja) 2012-09-18 2019-02-06 ジアルコ ファーマ リミテッドＺｉａｒｃｏ Ｐｈａｒｍａ Ｌｔｄ 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類
EP2900653A1 (en) 2012-09-28 2015-08-05 Pfizer Inc. Benzamide and heterobenzamide compounds
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
WO2014053968A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
CA2885253A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
GEP201606598B (en) 2012-11-08 2017-01-10 Pfizer Heteroaromatic compounds as dopamine d1 ligands
JP5857168B2 (ja) 2012-11-08 2016-02-10 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物およびその使用
US10179779B2 (en) 2012-11-21 2019-01-15 Raqualia Pharma Inc. Polymorph forms
MY176727A (en) 2012-12-03 2020-08-20 Pfizer Selective androgen receptor modulators
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
HUE054212T2 (hu) 2013-02-21 2021-08-30 Pfizer Szelektív CDK4/6 inhibitor szilárd formái
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EA201591644A1 (ru) * 2013-03-13 2016-05-31 Ратиофарм Гмбх Лекарственная форма, содержащая кризотиниб
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
US9603934B2 (en) 2013-05-17 2017-03-28 Acupac Packaging, Inc. Anhydrous hydrogel composition and delivery system
AU2014300673B2 (en) 2013-06-27 2017-12-14 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
JP2016540811A (ja) 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
AR099052A1 (es) 2014-01-09 2016-06-29 Takeda Pharmaceuticals Co Derivados de azaindol
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
AU2015249497A1 (en) 2014-04-25 2016-10-20 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN106232118A (zh) 2014-04-25 2016-12-14 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
US9745317B2 (en) 2014-04-28 2017-08-29 Pfizer Inc. Heterocyclic compounds and their use as dopamine D1 ligands
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
SI3143019T1 (sl) 2014-05-15 2021-03-31 Pfizer Inc. Kristalna oblika 6-((4R)-4-metil-1,2-dioksido-1,2,6-tiadiazinan-2-IL)isokvinolin-1- karbonitrila
KR102471082B1 (ko) 2014-05-20 2022-11-25 라퀄리아 파마 인코포레이티드 벤즈이소옥사졸 유도체염
EP3148992A1 (en) 2014-05-30 2017-04-05 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
CA2950390C (en) 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
PE20161552A1 (es) 2014-06-17 2017-01-11 Pfizer Compuestos de dihidroisoquinolinona sustituida
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016044433A2 (en) 2014-09-16 2016-03-24 Biopharma Works Metformin derivatives
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
ES2801005T3 (es) 2015-01-22 2021-01-07 Phytoplant Res S L Métodos de purificar canabinoides, composiciones y kits asociados
PE20171449A1 (es) 2015-02-24 2017-10-02 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
EP3286178A1 (en) 2015-04-21 2018-02-28 Almirall S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
CN113616606A (zh) 2015-06-04 2021-11-09 辉瑞公司 帕博西尼的固体剂型
CN107849017B (zh) 2015-07-31 2021-03-30 辉瑞公司 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
EP3386983A1 (en) 2015-12-10 2018-10-17 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
PL3394045T3 (pl) 2015-12-24 2021-09-27 Takeda Pharmaceutical Company Limited Kokryształ, sposób jego wytwarzania i lek zawierający kokryształ
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
CA3011201C (en) 2016-01-15 2020-09-22 Pfizer Inc. 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
RU2718906C2 (ru) 2016-01-20 2020-04-15 Теравида, Инк. Способы и композиции для лечения гипергидроза
WO2017156341A1 (en) 2016-03-09 2017-09-14 Beijing Percans Oncology Co. Ltd. Tumor cell suspension cultures and related methods
AU2017240609B2 (en) 2016-03-31 2021-07-15 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
EP3496724B8 (en) 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
RS61934B1 (sr) 2016-08-15 2021-07-30 Pfizer Inhibitori piridopirimdinona cdk2/ 4/6
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
ES2953474T3 (es) 2016-12-20 2023-11-13 Oligomerix Inc Nuevas quinazolinonas que inhiben la formación de oligómeros de tau y su modo de uso
JP7273722B2 (ja) 2016-12-20 2023-05-15 オリゴメリックス インコーポレイテッド タウオリゴマーの形成を阻害する新規ベンゾフラン、ベンゾチオフェン及びインドール類似体並びにそれらの使用方法
AU2018208846A1 (en) 2017-01-20 2019-07-25 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
WO2018134698A1 (en) 2017-01-23 2018-07-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
CN110461860A (zh) 2017-01-24 2019-11-15 辉瑞公司 卡奇霉素衍生物及其抗体药物缀合物
WO2018183145A1 (en) 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
WO2018234808A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Small molecule modulators of human sting
KR102782200B1 (ko) 2017-08-30 2025-03-17 에이제이 사이언시즈 (이씽) 코., 엘티디 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
EP3681879A1 (en) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ｅｚｈ２阻害剤組合せ療法
IL276010B1 (en) 2018-01-29 2025-09-01 Phytoplant Res S L Methods for purifying cannabinoids using liquid:liquid chromatography
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
WO2019166928A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
EP3784664B1 (en) 2018-04-26 2025-02-19 Pfizer Inc. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
CA3106510A1 (en) 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
AU2020211789A1 (en) 2019-01-23 2021-07-22 Pfizer Inc. Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
AU2020228047B2 (en) 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
WO2020198053A1 (en) 2019-03-22 2020-10-01 Takeda Pharmaceutical Company Limited 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
US12247015B2 (en) 2019-04-29 2025-03-11 Solent Therapeutics, Llc 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
US20220298115A1 (en) 2019-07-25 2022-09-22 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
KR20220063228A (ko) 2019-09-16 2022-05-17 다케다 야쿠힌 고교 가부시키가이샤 아졸-융합된 피리다진-3(2h)-온 유도체
WO2021161230A1 (en) 2020-02-12 2021-08-19 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN115461340A (zh) 2020-04-08 2022-12-09 特殊治疗有限公司 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物
KR20230003128A (ko) 2020-05-01 2023-01-05 화이자 인코포레이티드 Hpk1 억제제로서의 아잘락탐 화합물
IL297456A (en) 2020-05-04 2022-12-01 Takeda Pharmaceuticals Co n-(piperidin-4-yl)benzamide derivatives are active in Nahor
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
WO2021239863A1 (en) 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
CN115698001A (zh) 2020-06-04 2023-02-03 特殊治疗有限公司 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物
FI4161929T3 (fi) 2020-06-08 2025-07-30 Mission Therapeutics Ltd 1-(5-(2-syaanipyridin-4-yyli)oksatsoli-2-karbonyyli)-4-metyyliheksahydropyrrolo[3,4-b]pyrroli-5(1h)-karbonitriili usp30-inhibiittorina käytettäväksi mitokondrioiden toimintahäiriön, syövän ja fibroosin hoitamisessa
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
CA3189632A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
IL300581A (en) 2020-08-13 2023-04-01 Pfizer Combined treatment
JP7260606B2 (ja) 2020-09-15 2023-04-18 ファイザー・インク 固体形態のｃｄｋ４阻害薬
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
KR20230106605A (ko) 2020-10-09 2023-07-13 나파 테라퓨틱스 엘티디. Cd38의 헤테로아릴 아미드 억제제
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
IL303932A (en) 2020-12-22 2023-08-01 Pfizer Solid forms of EIF4E inhibitor
KR20230122100A (ko) 2020-12-24 2023-08-22 화이자 인코포레이티드 Cdk2 억제제의 고체 형태
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
US20240180906A1 (en) 2021-03-24 2024-06-06 Pfizer Inc. Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
MX2023011633A (es) 2021-03-31 2023-12-15 Sevenless Therapeutics Ltd Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor.
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
WO2022214869A2 (en) 2021-04-07 2022-10-13 Lifearc Ulk1/2 inhibitors and their use thereof
WO2022229846A1 (en) 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
KR20240027048A (ko) 2021-06-26 2024-02-29 어레이 바이오파마 인크. Her2 돌연변이 억제제
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
TW202321232A (zh) 2021-08-11 2023-06-01 印度商裘拉德製藥私人有限公司 小分子sting拮抗劑
JP2024529089A (ja) 2021-08-11 2024-08-01 キュラデブ ファーマ ピーブイティー． リミテッド Ｓｔｉｎｇアンタゴニストとしての小分子ウレア誘導体
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
CA3239257A1 (en) 2021-12-01 2023-06-08 Joaquin Pastor Fernandez Compounds
US20250034122A1 (en) 2021-12-01 2025-01-30 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
AU2022402512A1 (en) 2021-12-02 2024-06-20 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
JP2025511255A (ja) 2022-03-30 2025-04-15 武田薬品工業株式会社 Ｎ－（ピロリジン－３－イルまたはピペリジン－４－イル）アセトアミド誘導体
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
EP4554674A1 (en) 2022-07-15 2025-05-21 Jazz Pharmaceuticals Ireland Limited Biaryl ether urea compounds as faah inhibitors
WO2024023727A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors
TW202417456A (zh) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
KR20250068623A (ko) 2022-08-11 2025-05-16 이벡스타 바이오 암 치료용 화합물
EP4598538A1 (en) 2022-10-05 2025-08-13 Sevenless Therapeutics Limited New treatments for pain
AU2023380028A1 (en) 2022-11-15 2025-05-22 Curadev Pharma Ltd Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
IL321429A (en) 2023-01-13 2025-08-01 Neurim Pharmaceuticals 1991 Ltd Piromelatine for treating parasomnias associated with loss of rem sleep atonia
CN120603836A (zh) 2023-01-26 2025-09-05 武田药品工业株式会社 可用于治疗神经退化疾病的1-氨基-4-苯基酞嗪衍生物
AU2024255473A1 (en) 2023-04-14 2025-10-16 Takeda Pharmaceutical Company Limited Pyrazolopyrimidine derivatives as inhibitors of nlrp3
AU2024284619A1 (en) 2023-06-09 2025-12-04 Institut Gustave Roussy Drug conjugate targeting ctla4, products comprising the same and therapeutic uses thereof
WO2024258856A1 (en) 2023-06-12 2024-12-19 Arvinas Operations, Inc. Solid oral dosage forms of estrogen receptor degraders
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
US20250057848A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases
WO2025231370A1 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited Inhibitors of cd38
WO2025229624A2 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited New cd38 inhibitors
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
WO2025247951A1 (en) 2024-05-28 2025-12-04 Institut Gustave Roussy Fyn kinase inhibitors, combinations and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
US6106864A (en) 2000-08-22
MX9802026A (es) 1998-08-30
EP1245231B1 (en) 2004-06-16
ZA967745B (en) 1998-03-13
ES2224002T3 (es) 2005-03-01
BR122012014331A2 (OSRAM) 1999-01-05
CY2005007I2 (el) 2009-11-04
CO4750822A1 (es) 1999-03-31
CY2468B1 (en) 2005-06-03
JP3403203B2 (ja) 2003-05-06
BR122012014331B1 (pt) 2019-10-08
FR05C0019I1 (OSRAM) 2005-05-27
CZ73298A3 (cs) 1999-03-17
HU225236B1 (en) 2006-08-28
DE69626397T2 (de) 2003-07-17
CN1303998C (zh) 2007-03-14
EP0850059A1 (en) 1998-07-01
CA2230314C (en) 2003-06-24
AU6927596A (en) 1997-04-01
NO981073D0 (no) 1998-03-11
IL122746A0 (en) 1998-08-16
IL122746A (en) 2000-12-06
DE69632753T2 (de) 2005-07-14
CN1195984A (zh) 1998-10-14
NL300190I2 (nl) 2005-08-01
BR122012014331B8 (pt) 2021-05-25
PL185604B1 (pl) 2003-06-30
DE122005000024I2 (de) 2006-11-23
HUP9802339A3 (en) 1999-09-28
BR122012014331A8 (pt) 2018-07-31
RU2163803C2 (ru) 2001-03-10
AR005231A1 (es) 1999-04-28
NL300190I1 (nl) 2005-07-01
GB9518953D0 (en) 1995-11-15
JPH10511112A (ja) 1998-10-27
NO2005009I2 (no) 2006-11-27
ES2188782T3 (es) 2003-07-01
CY2585B2 (en) 2009-11-04
CY2005007I1 (el) 2009-11-04
AU703866B2 (en) 1999-04-01
HUP9802339A2 (hu) 1999-08-30
EP1245231A3 (en) 2003-01-15
TW442300B (en) 2001-06-23
WO1997009980A1 (en) 1997-03-20
TR199800461T1 (xx) 1998-05-21
FR05C0019I2 (OSRAM) 2005-11-04
DK0850059T3 (da) 2003-03-31
EP1245231A2 (en) 2002-10-02
CZ294024B6 (cs) 2004-09-15
EP0850059B1 (en) 2003-02-26
NZ316924A (en) 1999-06-29
NO314783B1 (no) 2003-05-26
NO981073L (no) 1998-03-11
DE69626397D1 (de) 2003-04-03
CA2230314A1 (en) 1997-03-20
EG23826A (en) 2007-09-25
DE69632753D1 (de) 2004-07-22
DK1245231T3 (da) 2004-10-25
ATE269076T1 (de) 2004-07-15
PT1245231E (pt) 2004-10-29
DE122005000024I1 (de) 2005-08-04
LU91163I2 (fr) 2005-06-20
BR9610153A (pt) 1999-01-05
NO2005009I1 (no) 2005-04-18
MY125662A (en) 2006-08-30
PL325598A1 (en) 1998-08-03
KR19990044653A (ko) 1999-06-25
HU0500976D0 (en) 2005-12-28
KR100348585B1 (ko) 2002-10-31
ATE233090T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
HU227397B1 (en) Pharmaceutical formulations containing darifenacin
JP4355779B2 (ja) マトリックス制御放出デバイス
AU2004268663B2 (en) Sustained release dosage forms of ziprasidone
HU224217B1 (hu) Gombaellenes hatóanyaggal és polimerrel bevont magrészt tartalmazó pelletek
IL102777A (en) Pharmaceutical combination formulation
HU229097B1 (en) Pharmaceutical compositions containing amoxicilline and clavulanic acid potassium salt
ZA200101485B (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same.
EA003247B1 (ru) Композиция, содержащая мезилат тровафлоксацина (варианты)
US7163696B2 (en) Pharmaceutical formulations
CZ20024216A3 (cs) Přípravky s chinolonovými antibiotiky s prodlouženým účinkem a způsob jejich výroby
CN1232386A (zh) 弱酸药物的结肠运送
EP1434570B1 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline
EP4445899A1 (en) Sustained release dosage forms comprising complexes of low solutibility compounds, and methods for their preparation
KR100222306B1 (ko) 닐바디핀 속효성 고형제제 및 이의 제조방법
AU703866C (en) Pharmaceutical formulations containing darifenacin
AU726814B2 (en) Pharmaceutical formulations containing darifenacin
MXPA98002026A (en) Pharmaceutical formulations containing darifenac
MXPA00001417A (en) Matrix controlled release device
AU2002341260A1 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERUS LABS NETHERLANDS B.V., NL

Free format text: FORMER OWNER(S): NOVARTIS AG, CH